BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.79
-0.12 (-1.21%)
Jul 14, 2026, 11:08 AM EDT - Market open
BioCryst Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -457.98 | 263.86 | -88.88 | -226.54 | -247.12 | -184.06 |
Depreciation & Amortization | 2.12 | 1.39 | 1.25 | 1.66 | 1.44 | 0.78 |
Stock-Based Compensation | 55.93 | 85.07 | 65.41 | 55.62 | 44.7 | 34.64 |
Other Adjustments | 745.27 | 53.95 | 57.48 | 106.53 | 98.07 | -1.64 |
Change in Receivables | -23.29 | -36.81 | -22.7 | -6.1 | -21.47 | -20.82 |
Changes in Inventories | -5.62 | -1.64 | -4.16 | -1.45 | -12.42 | -8.77 |
Changes in Accounts Payable | 30 | 57.8 | 14.78 | 12.53 | -22.36 | 39.41 |
Changes in Accrued Expenses | - | - | - | - | - | 4.17 |
Changes in Unearned Revenue | -0.75 | - | - | -1.23 | -0.11 | 1.28 |
Changes in Other Operating Activities | -64.58 | -76.26 | -75.2 | -36.16 | -2.58 | -7.16 |
Operating Cash Flow | 313.1 | 347.37 | -52.02 | -95.14 | -161.85 | -142.16 |
Capital Expenditures | -2.73 | -2.47 | -1.12 | -2.17 | -1.25 | -2.39 |
Purchases of Investments | -97.69 | -262.24 | -266.76 | -514.41 | -244.28 | -10.01 |
Proceeds from Sale of Investments | 352.88 | 256.65 | 320.48 | 385.08 | 117.4 | 28.2 |
Payments for Business Acquisitions | -489.48 | - | - | - | - | - |
Proceeds from Business Divestments | - | -6.18 | - | - | - | - |
Other Investing Activities | - | 0.55 | - | - | - | - |
Investing Cash Flow | -309.44 | -13.69 | 52.59 | -131.5 | -128.24 | 15.8 |
Long-Term Debt Issued | 400 | - | - | 300 | 73.07 | 293.87 |
Long-Term Debt Repaid | -290.42 | -324.87 | -1.7 | -241.62 | - | - |
Net Long-Term Debt Issued (Repaid) | 109.58 | -324.87 | -1.7 | 58.38 | 73.07 | 293.87 |
Issuance of Common Stock | 5.64 | 9.17 | 3.48 | 8.68 | 14.96 | 65.79 |
Repurchase of Common Stock | -8.68 | -8.85 | -7.54 | -2.17 | - | - |
Net Common Stock Issued (Repurchased) | -3.04 | 0.33 | -4.06 | 6.51 | 14.96 | 65.79 |
Other Financing Activities | -22.4 | -34.23 | -7.54 | -34.58 | - | - |
Financing Cash Flow | 62.09 | -349.93 | -5.76 | 32.49 | 88.03 | 359.67 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0.75 | 1.27 | -0.94 | 0.36 | 0.57 | 0.07 |
Net Cash Flow | 61.96 | -14.99 | -6.12 | -193.79 | -201.5 | 233.39 |
Free Cash Flow | 310.37 | 344.9 | -53.14 | -97.31 | -163.1 | -144.54 |
Free Cash Flow Growth | -10.01% | - | - | - | - | - |
FCF Margin | 96.16% | 39.42% | -11.79% | -29.36% | -60.22% | -91.97% |
Free Cash Flow Per Share | 1.38 | 1.58 | -0.26 | -0.51 | -0.88 | -0.81 |
Levered Free Cash Flow | -389.95 | -82.18 | -155.05 | -194.98 | -211.33 | 137.15 |
Unlevered Free Cash Flow | -994.27 | 315.32 | -67.06 | -130.67 | -187.38 | -152.59 |